-
Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs
•
Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell its intensive care unit (ICU) business to fellow U.S. firm BD for USD 4.2 billion. This strategic move is accompanied by a global restructuring that will result in layoffs impacting approximately 3% of the company’s…
-
Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced positive preliminary results from a Phase I/II clinical study assessing the tolerability, safety, efficacy, and pharmacokinetics of ZG006 in patients with advanced small-cell lung cancer (SCLC) or neuroendocrine carcinoma. The study, which included a dosage…
-
China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds
•
The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on Strengthening Management of Social Supervisors of Medical Insurance Funds” for public consultation. This initiative aims to engage a broad spectrum of societal actors in the oversight of Basic Medical Insurance (BMI) funds, ensuring the integrity…
-
Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership
•
Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray Medical International Limited, a fellow Chinese firm, to collaborate on research and development, manufacturing, and marketing in the field of flow testing. The agreement encompasses a wide range of activities, although financial specifics have not…
-
China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion
•
China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly released a “Notification on Carrying out Pilot Work to Expand the Opening Up of the Medical Field,” signaling a significant shift in the country’s healthcare landscape. The notification outlines measures aimed at further opening up…
-
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
•
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou before relocating its headquarters to the US, has released its financial report for the first half of 2024. The report highlights the company’s strategic decision to retract its presence in the Chinese market as it…
-
Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development
•
On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures to Support the High-Quality Development of Innovative Pharmaceuticals and Medical Devices,” aiming to foster the growth of innovative pharmaceuticals and medical devices. The measures encourage private capital to participate in the construction of research hospitals…
-
Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial
•
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its co-development partner Daiichi Sankyo (TYO: 4568), have announced preliminary data from a Phase II clinical trial for the investigational B7-H3-directed antibody-drug conjugate (ADC) ifinatamab deruxtecan. The trial has identified a recommended dosage of 12mg/kg for…
